Doximity, Inc. (NASDAQ:DOCS – Get Free Report) Director Timothy S. Cabral sold 10,000 shares of Doximity stock in a transaction on Wednesday, June 25th. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the sale, the director now directly owns 6,360 shares of the company’s stock, valued at approximately $381,600. This trade represents a 61.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Doximity Stock Up 1.3%
DOCS opened at $61.19 on Friday. The company has a market cap of $11.49 billion, a P/E ratio of 61.19, a price-to-earnings-growth ratio of 4.10 and a beta of 1.33. The firm’s 50-day moving average price is $56.21 and its 200-day moving average price is $58.74. Doximity, Inc. has a 52-week low of $25.00 and a 52-week high of $85.21.
Doximity (NASDAQ:DOCS – Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.11. Doximity had a net margin of 36.60% and a return on equity of 21.75%. During the same quarter last year, the business posted $0.25 EPS. Doximity’s revenue for the quarter was up 17.1% on a year-over-year basis. On average, research analysts anticipate that Doximity, Inc. will post 0.99 EPS for the current fiscal year.
Hedge Funds Weigh In On Doximity
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on DOCS shares. BTIG Research upgraded Doximity from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research note on Monday, June 2nd. Truist Financial cut their target price on shares of Doximity from $58.00 to $52.00 and set a “hold” rating on the stock in a research report on Friday, May 16th. Raymond James Financial lowered their price target on shares of Doximity from $83.00 to $65.00 and set an “outperform” rating for the company in a research report on Friday, May 16th. Morgan Stanley dropped their price objective on shares of Doximity from $71.00 to $60.00 and set an “equal weight” rating on the stock in a research note on Thursday, April 24th. Finally, Needham & Company LLC reduced their price objective on shares of Doximity from $82.00 to $67.00 and set a “buy” rating for the company in a research note on Friday, May 16th. Eleven investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Doximity presently has an average rating of “Moderate Buy” and a consensus price target of $63.11.
Check Out Our Latest Stock Analysis on DOCS
Doximity Company Profile
Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.
Recommended Stories
- Five stocks we like better than Doximity
- Retail Stocks Investing, Explained
- EA Just Caught a Monster Upgrade: Bullish Breakout Ahead?
- What does consumer price index measure?
- 3 Stocks Hitting All-Time Highs With More Room to Run
- Election Stocks: How Elections Affect the Stock Market
- QuantumScape Soars 30%: What Drove the Next-Gen EV Stock’s Rally
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.